NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Sanifit announces the creation of a Steering Committee for its Phase 2b ESRD Clinical Program with SNF472<
21 Dec 2015

Sanifit announces the creation of a Steering Committee for its Phase 2b ESRD Clinical Program with SNF472

The newly created Steering Committee includes 4 well known scientists and clinicians who will provide the overall supervision of the phase 2b study with SNF472.
Sanifit and Mitelos make available to Doctors and patients a new alternative in osteoporosis<
25 Nov 2015

Sanifit and Mitelos make available to Doctors and patients a new alternative in osteoporosis

Sanifit and Mitelos have successfully concluded the development, registration and industrial scaled up of SNF671
19 Nov 2015

TiGenix completes enrolment of its Phase I/II study in acute myocardial infarction

Leuven (BELGIUM) – 19th November 2015 – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today that it has completed enrolment of its Phase II study in acute myocardial Infarction (CAREMI study).
19 Nov 2015

CVRx® Announces Expedited Access Pathway Designation by FDA for Barostim Therapy® for the Treatment of Heart Failure in Order to Accelerate Access for US Patients

Minneapolis – November 19, 2015 – CVRx, Inc., a private medical device company, announced that it received Expedited Access Pathway (EAP) Designation by FDA for Barostim Therapy® for the treatment of heart failure.
Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)<
14 Oct 2015

Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)

Funds will help company reach clinical validation for lead candidate in X-ALD, a rare neurodegenerative and life-threatening disease
30 Sep 2015

AM-Pharma publishes further preclinical data on recAP to treat Acute Kidney Injury

Bunnik, The Netherlands, 30 September 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), today announces the publication of two papers on recAP for the potential treatment of Acute Kidney Injury (AKI).
29 Sep 2015

AM-Pharma and Pfizer Inc. shortlisted for “Best Partnership Alliance” in 2015 Scrip Awards

Bunnik, The Netherlands, 29 September 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), and Pfizer Inc. have been nominated for the prestigious category of “Best Partnership Alliance” for the 11th Annual Scrip Awards, organised by Scrip Intelligence, the leading source of news and strategic analysis for the global pharmaceutical industry.
IRB Barcelona identifies the gene responsible for metastasis of breast cancer to the bone<
16 Sep 2015

IRB Barcelona identifies the gene responsible for metastasis of breast cancer to the bone

This new knowledge may accelerate the development of the first preventive treatment of bone metastasis 
15 Sep 2015

TiGenix Business and Financial Update for the First Half of 2015

Leuven (BELGIUM) - 15 September 2015 - TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, today announced its Business and Financial Update for the first half of 2015 and recent significant events.
10 Sep 2015

NITID (optical coherence tomography and digital dermatoscope handheld device) – CE Mark approval received

Madrid, September 10, 2015. DermaLumics, a recently founded spin-off of optical tomography systems developer MedLumics, announces that NITID, its first skin diagnostic solution, received CE Mark approval in Europe.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.